AbbVie is a U.S.-registered, Illinois-headquartered pharmaceutical giant listed on the NYSE, built from a 2013 spin-off of Abbott Laboratories.
The Short Answer
Yes. AbbVie is an American company, incorporated and headquartered in the United States, publicly traded on a U.S. stock exchange, and employing a large domestic workforce. Its story, though, begins with another well-known American name.
Born From Abbott
AbbVie was founded in 2012 as a planned spin-off from Abbott, one of the country's oldest healthcare firms. The separation became official in early 2013, when AbbVie began operating as its own independent, publicly traded pharmaceutical company. That lineage matters: AbbVie didn't arrive from nowhere, it inherited decades of American pharmaceutical research infrastructure the moment it split off.
A December Debut on Wall Street
The company's shares began trading in December 2012, ahead of the formal separation, under the ticker ABBV on the New York Stock Exchange. That listing is one of the clearest markers of its American corporate identity — AbbVie reports its financials, governance, and operations under U.S. securities rules, the same as any other NYSE-listed firm.
Where It's Headquartered
AbbVie's headquarters sits in North Chicago, Illinois, a location that anchors its corporate leadership, research decisions, and administrative functions squarely in the American Midwest. This is where the company is officially based, even as its medicines reach patients well beyond U.S. borders.
What AbbVie Actually Makes
AbbVie is a pharmaceutical firm with deep footholds in two major therapeutic areas.
Immunology Leadership
Its immunology lineup includes Humira, Skyrizi, and Rinvoq — treatments that have made AbbVie a major player in managing chronic inflammatory and autoimmune conditions.
Oncology Portfolio
On the cancer side, AbbVie markets Imbruvica and Venclexta, extending its reach into oncology treatment alongside its immunology business.
Expanding Through Acquisitions
The company's product lineup has grown through acquisition as much as internal research. The 2020 purchase of Allergan brought aesthetics products, including Botox, into AbbVie's portfolio. More recently, the 2024 acquisitions of Cerevel, focused on neuroscience, and ImmunoGen, focused on oncology, added further depth to what AbbVie can offer patients and physicians.
The Scale of Its American Workforce
AbbVie employs approximately 57,000 people, a workforce that supports research, manufacturing, sales, and administrative operations tied to its Illinois headquarters and broader corporate structure.
The Numbers Behind the Name
As a publicly traded company, AbbVie discloses its financial results in U.S. dollars under American accounting and securities standards.
Revenue and Earnings
In fiscal year 2025, AbbVie reported revenue of $61.2 billion and net income of $4.2 billion.
Balance Sheet and Market Value
The company's total assets stand at $134.0 billion, while its market capitalization reaches $401.5 billion, reflecting how investors value the company on the open market.
Bottom Line
Between its Illinois headquarters, its NYSE listing, its origins as an Abbott spin-off, and its sizable U.S.-based employee base, AbbVie checks every box for an American corporate identity. It is a domestically headquartered, publicly traded pharmaceutical company that also happens to sell its immunology, oncology, and aesthetics products to patients around the world.
